Literature DB >> 21957298

Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates.

Tram N Q Pham1, Jonathan Richard, Francine C A Gerard, Christopher Power, Éric A Cohen.   

Abstract

HIV-1 viral protein R (Vpr) from laboratory-adapted virus strains activates the DNA damage/stress sensor ATR kinase and induces cell cycle arrest at the G(2)/M phase through a process that requires Vpr to engage the DDB1-CUL4A (VprBP/DCAF-1) E3 ligase complex. Activation of this DNA damage/stress checkpoint in G(2) by Vpr was shown to modulate NKG2D-dependent NK cell effector functions via enhancing expression of NKG2D ligands, notably ULBP2. However, it is unknown whether Vpr from HIV-1 primary isolates (groups M, N, O, and P) could modulate NKG2D-mediated cytotoxic functions of NK cells. Here, we report that Vpr from most HIV-1 primary isolates can upregulate ULBP2 expression and induce NKG2D-dependent NK cell killing. Importantly, these activities were always accompanied by an active G(2) cell cycle arrest function. Interestingly, Vpr variants from group P and a clade D isolate of group M were defective at enhancing NKG2D-mediated NK cell lysis owing to their inability to augment ULBP2 expression. However, distinct mechanisms were responsible for their failure to do so. While Vpr from group P was deficient in its ability to engage the DDB1-CUL4A (VprBP/DCAF-1) E3 ligase complex, the Vpr variant from group D was unable to properly localize to the nucleus, underlining the importance of these biological properties in Vpr function. In conclusion, the ability of Vpr from HIV-1 primary isolates to regulate NK cell effector function underscores the importance of this HIV-1 accessory protein in the modulation of the host's innate immune responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957298      PMCID: PMC3209390          DOI: 10.1128/JVI.05835-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest.

Authors:  Jean-Philippe Belzile; Jonathan Richard; Nicole Rougeau; Yong Xiao; Eric A Cohen
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

2.  The role of Vpr in HIV-1 disease progression is independent of its G2 arrest induction function.

Authors:  Maoyi Lai; Junjie Chen
Journal:  Cell Cycle       Date:  2006-10-01       Impact factor: 4.534

3.  HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase.

Authors:  Erwann Le Rouzic; Nadia Belaïdouni; Emilie Estrabaud; Marina Morel; Jean-Christophe Rain; Catherine Transy; Florence Margottin-Goguet
Journal:  Cell Cycle       Date:  2007-01-17       Impact factor: 4.534

4.  HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.

Authors:  Jonathan Richard; Sardar Sindhu; Tram N Q Pham; Jean-Philippe Belzile; Eric A Cohen
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

5.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

6.  Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest.

Authors:  Jean-Philippe Belzile; Levon G Abrahamyan; Francine C A Gérard; Nicole Rougeau; Eric A Cohen
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

7.  HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT.

Authors:  Joshua L Andersen; Jason L DeHart; Erik S Zimmerman; Orly Ardon; Baek Kim; Guillaume Jacquot; Serge Benichou; Vicente Planelles
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

8.  HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response.

Authors:  Jeffrey Ward; Zachary Davis; Jason DeHart; Erik Zimmerman; Alberto Bosque; Enrico Brunetta; Domenico Mavilio; Vicente Planelles; Edward Barker
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

9.  Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions.

Authors:  Guillaume Jacquot; Erwann Le Rouzic; Priscilla Maidou-Peindara; Marion Maizy; Jean-Jacques Lefrère; Vincent Daneluzzi; Carlos M R Monteiro-Filho; Duanping Hong; Vicente Planelles; Laurence Morand-Joubert; Serge Benichou
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240

10.  Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.

Authors:  Manuela Fogli; Domenico Mavilio; Enrico Brunetta; Stefania Varchetta; Khaled Ata; Gregg Roby; Colin Kovacs; Dean Follmann; Daniela Pende; Jeffrey Ward; Edward Barker; Emanuela Marcenaro; Alessandro Moretta; Anthony S Fauci
Journal:  PLoS Pathog       Date:  2008-07-11       Impact factor: 6.823

View more
  9 in total

Review 1.  The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell cycle arrest.

Authors:  Hamayun J Sharifi; Andrea M Furuya; Carlos M C de Noronha
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

2.  Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes.

Authors:  Jonathan Richard; Tram N Q Pham; Yukihito Ishizaka; Eric A Cohen
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

3.  Cullin4A and cullin4B are interchangeable for HIV Vpr and Vpx action through the CRL4 ubiquitin ligase complex.

Authors:  Hamayun John Sharifi; Andrea K M Furuya; Robert M Jellinger; Michael D Nekorchuk; Carlos M C de Noronha
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions.

Authors:  Kevin Hadi; Leah A Walker; Debjani Guha; Ramachandran Murali; Simon C Watkins; Patrick Tarwater; Alagarsamy Srinivasan; Velpandi Ayyavoo
Journal:  J Gen Virol       Date:  2013-12-03       Impact factor: 3.891

5.  The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection.

Authors:  Laurieann Casey Klockow; Hamayun J Sharifi; Xiaoyun Wen; Meg Flagg; Andrea K M Furuya; Michael Nekorchuk; Carlos M C de Noronha
Journal:  Virology       Date:  2013-07-09       Impact factor: 3.616

Review 6.  HIV-1 Vpu interference with innate cell-mediated immune mechanisms.

Authors:  Johan K Sandberg; Sofia K Andersson; Susanna M Bächle; Douglas F Nixon; Markus Moll
Journal:  Curr HIV Res       Date:  2012-06       Impact factor: 1.581

7.  Higher Expression of Activating Receptors on Cytotoxic NK Cells is Associated with Early Control on HIV-1C Multiplication.

Authors:  Archana Gopal Kulkarni; Ramesh Shivram Paranjape; Madhuri Rajeev Thakar
Journal:  Front Immunol       Date:  2014-05-16       Impact factor: 7.561

8.  NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses.

Authors:  Alessandra Zingoni; Michele Ardolino; Angela Santoni; Cristina Cerboni
Journal:  Front Immunol       Date:  2013-01-09       Impact factor: 7.561

9.  Dual role of the chromatin-binding factor PHF13 in the pre- and post-integration phases of HIV-1 replication.

Authors:  Stephan Hofmann; Sandra Dehn; Ramona Businger; Sebastian Bolduan; Martha Schneider; Zeger Debyser; Ruth Brack-Werner; Michael Schindler
Journal:  Open Biol       Date:  2017-10       Impact factor: 6.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.